- Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
- Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
- Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
- Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
- Gain Therapeutics to Present at Public Ventures Discovery Day
- Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
- Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
- Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
- UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
- Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update
More ▼
Key statistics
As of last trade, Gain Therapeutics Inc (GANX:NMQ) traded at 2.45, 22.50% above the 52 week low of 2.00 set on Nov 22, 2023.
52-week range
Open | 2.41 |
---|---|
High | 2.57 |
Low | 2.41 |
Bid | 2.43 |
Offer | 2.50 |
Previous close | 2.43 |
Average volume | 105.29k |
---|---|
Shares outstanding | 18.05m |
Free float | 16.83m |
P/E (TTM) | -- |
Market cap | 43.87m USD |
EPS (TTM) | -1.53 USD |
Data delayed at least 15 minutes, as of May 23 2024 15:00 BST.
More ▼